Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis

Key Findings

• ●S/A/R gene panel: SRSF2/ASXL1/RUNX1 mutations predict inferior OS in AdvSM
• ●3-year OS: 90% (0 mutations), 73% (1 mutation), 42% (>=2 mutations)
• ●SRSF2 HR 5.9, ASXL1 HR 3.4, RUNX1 HR 2.4 for mortality

Referenced in (1 disease)